Back to results
US 2016/0243248 A1Published application
Glycotargeting therapeutics
AssigneeEcole Polytechnique Federale de Lausanne
InventorsJeffrey A. Hubbell, David Scott Wilson
Life of this patent
Estimating the term…
Abstract
Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
Claims16
A composition comprising a compound of Formula 1:
- where:
- m is an integer from about 1 to 100;
- X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof;
- or
- X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy;
- Y comprises a linker moiety;
- and
- Z comprises a liver-targeting moiety.
5 more elements
A method of treatment for an unwanted immune response against an antigen by administering to a mammal in need of such treatment an effective amount of a composition comprising a compound of Formula 1:
- where:
- m is an integer from about 1 to 100;
- X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof;
- or
- X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody, which circulating protein or peptide or antibody is causatively involved in transplant rejection, immune response against a therapeutic agent, autoimmune disease, hypersensitivity and/or allergy;
- Y comprises a linker moiety;
- and
- Z comprises a glucosylated liver-targeting moiety.
5 more elements
Dependencies are inferred from the claim text.